What is the difference between Pramlintide and Tirzepatide?

Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety Tirzepatide: Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

Is Tirzepatide FDA approved?

Tirzepatide is FDA approved (FDA status current as of 2022-05-13). This regulatory status is provided for research and educational context only.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Tirzepatide administered in research settings?

In research settings, Tirzepatide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Pramlintide vs Tirzepatide

Peptide Comparison

Pramlintide vs Tirzepatide

Both are Metabolic peptides.

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Tirzepatide

Dual GLP-1

Fat LossFDA ApprovedPrescription

Half-life: ~5 days (once-weekly dosing)

541 providers listed

Full Tirzepatide profile →

Bottom line

Tirzepatide carries stronger published evidence (RCT, 9 key studies) than Pramlintide (RCT, 3); both are research compounds.

Quick Verdict

Pramlintide

Half-life

~48 minutes

Tirzepatide

Half-life

~5 days (once-weekly dosing)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Tirzepatide
Less frequent dosing (longer half-life)	Tirzepatide
More provider options (0 vs 541)	Tirzepatide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Pramlintide

Tirzepatide

Mechanism Family

Metabolic

Half-life

~48 minutes

~5 days (once-weekly dosing)

FDA Status

approved

Admin Routes

subcutaneous

Availability

Prescription

Providers

None listed

541 listed

FDA Update

Mar 2005

May 2022

Avail. Notes

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Prescription only.

Research Evidence

Pramlintide

RCT · 3 key studies · most recent 2026

Tirzepatide

RCT · 9 key studies · most recent 2026

Research Citations

Pramlintide

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

In vitro2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

Tirzepatide

RCT2023 · Lancet

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)

RCT2022 · New England Journal of Medicine

Tirzepatide Once Weekly for the Treatment of Obesity

RCT2021 · New England Journal of Medicine

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Cohort2026 · Diabetes Ther

Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…

+5 more

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

About Tirzepatide

Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.

Research Areas

fat_loss

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Tirzepatide

Boxed warning

Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Source: FDA label

Suggested Monitoring

HbA1cFasting glucoseTSHCalcitoninLipaseeGFRALT/AST

FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.

Find Providers

Where to source these peptides

Providers offering

Pramlintide

Browse directory →

Providers offering

Tirzepatide

541 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.